AZT.OL
ArcticZymes Technologies ASA [AZT.OL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AZT.OL Stock Summary
Top 10 Correlated Stocks
AZT.OL
In the News
AZT.OL Financial details
Company Rating
Buy
Market Cap
1.44B
Income
18.72M
Revenue
118.94M
Book val./share
6.1
Cash/share
3.57
Dividend
-
Dividend %
-
Employees
60
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
116.57
Forward P/E
-
PEG
-27.01
P/S
17.37
P/B
6.68
P/C
7.25
P/FCF
264.4
Quick Ratio
12.39
Current Ratio
14.08
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
0.37
EPS next Y
-
EPS next Q
-
EPS this Y
-43.08%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
9.02%
Revenue Q/Q
-8.9%
EPS Q/Q
-66.75%
-
-
-
-
SMA20
-7.15%
SMA50
-22.64%
SMA100
-27.16%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
6%
ROC
0.07%
Gross Margin
96%
Oper. Margin
18%
Profit Margin
15%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
24.2-47.5
52W High
-44.89%
52W Low
+7.92%
RSI
32.65
Rel Volume
0.13
Avg Volume
34.44K
Volume
4.63K
Perf Week
-8.64%
Perf Month
-13.67%
Perf Quarter
1.17%
Perf Half Y
0.78%
-
-
-
-
Beta
0.939
-
-
Volatility
0.85%, 1.2%
Prev Close
-2.45%
Price
25.9
Change
-5.82%
AZT.OL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.6 | 1.93 | 2.59 | 2.72 | 2.35 | |
| Net income per share | -0.15 | 1.72 | 0.94 | 0.65 | 0.37 | |
| Operating cash flow per share | 0.08 | 0.97 | 1.52 | 1.15 | 0.48 | |
| Free cash flow per share | 0.06 | 0.93 | 1.28 | 0.91 | 0.1 | |
| Cash per share | 0.61 | 2.88 | 4.03 | 4.8 | 3.57 | |
| Book value per share | 0.93 | 4.02 | 4.96 | 5.65 | 6.1 | |
| Tangible book value per share | 0.95 | 4.05 | 4.93 | 5.46 | 5.58 | |
| Share holders equity per share | 0.93 | 4.02 | 4.96 | 5.65 | 6.1 | |
| Interest debt per share | 0.35 | 0.26 | 0.37 | 0.29 | 0.08 | |
| Market cap | 229.59M | 3.07B | 4.64B | 3.61B | 2.13B | |
| Enterprise value | 215.99M | 2.95B | 4.46B | 3.38B | 1.96B | |
| P/E ratio | -31.96 | 36.98 | 100 | 109.92 | 113.51 | |
| Price to sales ratio | 2.97 | 32.9 | 36.24 | 26.37 | 17.87 | |
| POCF ratio | 57.9 | 65.51 | 61.86 | 62.18 | 87 | |
| PFCF ratio | 80.14 | 68.29 | 73.18 | 79.1 | 407.87 | |
| P/B Ratio | 5.09 | 15.82 | 18.94 | 12.69 | 6.89 | |
| PTB ratio | 5.09 | 15.82 | 18.94 | 12.69 | 6.89 | |
| EV to sales | 2.8 | 31.54 | 34.83 | 24.71 | 16.45 | |
| Enterprise value over EBITDA | -4.7K | 55.61 | 70.87 | 71 | 88 | |
| EV to operating cash flow | 54.47 | 62.8 | 59.44 | 58.25 | 80.11 | |
| EV to free cash flow | 75.39 | 65.47 | 70.32 | 74.11 | 375.57 | |
| Earnings yield | -0.03 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Debt to equity | 0.35 | 0.06 | 0.07 | 0.05 | 0.01 | |
| Debt to assets | 0.21 | 0.05 | 0.06 | 0.04 | 0.01 | |
| Net debt to EBITDA | 295.63 | -2.4 | -2.88 | -4.78 | -7.57 | |
| Current ratio | 3.19 | 10.93 | 9.41 | 11.24 | 13.03 | |
| Interest coverage | -7.22 | 67.82 | 84.2 | 73.09 | 0 | |
| Income quality | -0.67 | 0.55 | 1.27 | 1.38 | 1.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.06 | 0.04 | 0 | 0 | |
| Research and developement to revenue | 0.14 | 0.21 | 0.12 | 0.17 | 0 | |
| Intangibles to total assets | 0.01 | 0 | 0.01 | 0.03 | 0.08 | |
| Capex to operating cash flow | -0.28 | -0.04 | -0.15 | -0.21 | -0.79 | |
| Capex to revenue | -0.01 | -0.02 | -0.09 | -0.09 | -0.16 | |
| Capex to depreciation | -0.22 | -0.19 | -3.63 | -2.48 | -3.01 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0.04 | 0 | |
| Graham number | 1.77 | 12.47 | 10.25 | 9.1 | 7.13 | |
| ROIC | -0.09 | 0.35 | 0.16 | 0.09 | 0.04 | |
| Return on tangible assets | -0.09 | 0.38 | 0.16 | 0.11 | 0.06 | |
| Graham Net | 0.25 | 2.86 | 3.69 | 4.4 | 4.39 | |
| Working capital | 40.22M | 158.79M | 208.62M | 245.29M | 258.51M | |
| Tangible asset value | 45.8M | 195.91M | 243.05M | 275.5M | 282.51M | |
| Net current asset value | 27.46M | 149.19M | 194.15M | 234.94M | 250.09M | |
| Invested capital | 0.35 | 0.06 | 0.07 | 0.05 | 0.01 | |
| Average receivables | 7.15M | 22.27M | 27.81M | 19.73M | 50.15M | |
| Average payables | 5.02M | 3.71M | 4.63M | 5.69M | 5.07M | |
| Average inventory | 5.93M | 4.59M | 5.39M | 6.98M | 9.98M | |
| Days sales outstanding | 67.61 | 118.09 | 72.42 | 37.49 | 264.61 | |
| Days payables outstanding | 76.48 | 1.12K | 544.45 | 394.03 | 23.28 | |
| Days of inventory on hand | 102.32 | 1.26K | 646.57 | 498.74 | 66.02 | |
| Receivables turnover | 5.4 | 3.09 | 5.04 | 9.73 | 1.38 | |
| Payables turnover | 4.77 | 0.33 | 0.67 | 0.93 | 15.68 | |
| Inventory turnover | 3.57 | 0.29 | 0.56 | 0.73 | 5.53 | |
| ROE | -0.16 | 0.43 | 0.19 | 0.12 | 0.06 | |
| Capex per share | -0.02 | -0.04 | -0.24 | -0.25 | -0.38 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.55 | 0.62 | 0.55 | 0.61 | 0.56 | |
| Net income per share | 0.02 | 0.1 | 0.11 | 0.12 | 0.04 | |
| Operating cash flow per share | 0.25 | -0.15 | 0.16 | 0.29 | 0.17 | |
| Free cash flow per share | 0.1 | -0.21 | 0.11 | 0.16 | 0.05 | |
| Cash per share | 4.79 | 4.6 | 4.71 | 4.85 | 3.57 | |
| Book value per share | 5.63 | 5.72 | 5.87 | 6 | 6.1 | |
| Tangible book value per share | 5.45 | 5.49 | 5.6 | 5.61 | 5.58 | |
| Share holders equity per share | 5.63 | 5.72 | 5.87 | 6 | 6.1 | |
| Interest debt per share | 0.38 | 0.23 | 0.27 | 0.27 | 0.08 | |
| Market cap | 3.62B | 2.1B | 2.03B | 1.55B | 2.13B | |
| Enterprise value | 3.4B | 1.88B | 1.81B | 1.32B | 1.96B | |
| P/E ratio | 1.13K | 104.02 | 90.78 | 64 | 263.44 | |
| Price to sales ratio | 130.59 | 67.23 | 72.11 | 49.81 | 74.89 | |
| POCF ratio | 286.51 | -274.94 | 246.32 | 103.71 | 240.6 | |
| PFCF ratio | 741.9 | -194.73 | 357.18 | 194.95 | 915.34 | |
| P/B Ratio | 12.73 | 7.25 | 6.82 | 5.08 | 6.89 | |
| PTB ratio | 12.73 | 7.25 | 6.82 | 5.08 | 6.89 | |
| EV to sales | 122.37 | 60.21 | 64.11 | 42.32 | 68.96 | |
| Enterprise value over EBITDA | 456.69 | 306.94 | 264.32 | 181.54 | 970.79 | |
| EV to operating cash flow | 268.48 | -246.24 | 218.98 | 88.12 | 221.54 | |
| EV to free cash flow | 695.23 | -174.41 | 317.54 | 165.64 | 842.86 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | -0.01 | 0 | 0.01 | 0 | |
| Debt to equity | 0.05 | 0.05 | 0.05 | 0.04 | 0.01 | |
| Debt to assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.01 | |
| Net debt to EBITDA | -30.66 | -35.77 | -33 | -32.12 | -83.49 | |
| Current ratio | 11.24 | 14.1 | 14.95 | 14.08 | 13.03 | |
| Interest coverage | 1.21 | -2.53 | 0 | 0 | 0 | |
| Income quality | 12.06 | -1.21 | 1.11 | 1.77 | 4.38 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.03 | 0.04 | 0.04 | 0.06 | 0.08 | |
| Capex to operating cash flow | -0.61 | 0.41 | -0.31 | -0.47 | -0.74 | |
| Capex to revenue | -0.28 | -0.1 | -0.09 | -0.22 | -0.23 | |
| Capex to depreciation | -5.79 | -1.98 | -1.54 | -4.36 | -4.28 | |
| Stock based compensation to revenue | 0.09 | -0.01 | 0.03 | 0.03 | 0 | |
| Graham number | 1.42 | 3.58 | 3.81 | 4.01 | 2.34 | |
| ROIC | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | 0 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Graham Net | 4.39 | 4.49 | 4.63 | 4.71 | 4.39 | |
| Working capital | 245.29M | 248.81M | 257.76M | 260.61M | 258.51M | |
| Tangible asset value | 275.5M | 277.88M | 284.85M | 285.43M | 282.51M | |
| Net current asset value | 234.94M | 238.91M | 247.77M | 251.26M | 250.09M | |
| Invested capital | 0.05 | 0.05 | 0.05 | 0.04 | 0.01 | |
| Average receivables | 19.37M | 18.44M | 23.47M | 22.35M | 53.4M | |
| Average payables | 5.09M | 4.21M | 3.57M | 4.66M | 4.78M | |
| Average inventory | 6.81M | 9.79M | 12.41M | 12.76M | 13.03M | |
| Days sales outstanding | 45.63 | 65.85 | 76.9 | 59.46 | 273.45 | |
| Days payables outstanding | 432.37 | 130.18 | 451.05 | 444.33 | 21.47 | |
| Days of inventory on hand | 547.27 | 575.99 | 1.29K | 1.17K | 60.89 | |
| Receivables turnover | 1.97 | 1.37 | 1.17 | 1.51 | 0.33 | |
| Payables turnover | 0.21 | 0.69 | 0.2 | 0.2 | 4.19 | |
| Inventory turnover | 0.16 | 0.16 | 0.07 | 0.08 | 1.48 | |
| ROE | 0 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Capex per share | -0.15 | -0.06 | -0.05 | -0.14 | -0.13 |
AZT.OL Frequently Asked Questions
What is ArcticZymes Technologies ASA stock symbol ?
ArcticZymes Technologies ASA is a NO stock and trading under the symbol AZT.OL
What is ArcticZymes Technologies ASA stock quote today ?
ArcticZymes Technologies ASA stock price is $25.9 today.
Is ArcticZymes Technologies ASA stock public?
Yes, ArcticZymes Technologies ASA is a publicly traded company.
Company Profile
- Volume Average 34.44K
- Market Capitalization 1.44B
- Employee 60
- CEO Mr. Michael Benjamin Akoh
- Headquarters Tromsø,NO
- IPO Date 2005-11-04
-
Website
https://arcticzymes.com 
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.
